Gyre Therapeutics (GYRE) EBT Growth (1y) (2011 - 2026)

Gyre Therapeutics (GYRE) EBT Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 8.48%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.60%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 88.57%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 213.87%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 76.48%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -12.04%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 530.43%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 96.45%
10 Gyre Therapeutics 708.31 Mn 685.47 Mn 26.90 Mn -816.44%

Historic Data

Download Data
DateValue
Jun 30, 2026 -816.44%
Mar 31, 2026 -299.29%
Dec 31, 2025 -108.55%
Sep 30, 2025 94.12%
Jun 30, 2025 -62.92%
Mar 31, 2025 -62.86%
Dec 31, 2024 100.77%
Sep 30, 2024 -64.87%
Jun 30, 2024 3.09%
Mar 31, 2024 99.03%
Dec 31, 2023 -339.82%
Sep 30, 2023 329.07%
Jun 30, 2023 -88.66%
Mar 31, 2023 143.14%
Dec 31, 2022 -8.61%
Sep 30, 2022 82.38%
Jun 30, 2022 325.48%
Mar 31, 2022 35.74%
Dec 31, 2021 -10.05%
Sep 30, 2021 -70.63%